IP Library › Granted Patent US 12,723,074
Granted Patent B2
US 12,723,074 · App. 17/910,538 · Granted Sep 1, 2026

Medicament for treatment and/or prevention of cancer

Inventors: Fumiyoshi Okano (Kamakura, JP); Daisuke Akazawa (Kamakura, JP)
Assignee: TORAY INDUSTRIES, INC.
C07K16/28A61K31/337A61P35/00C07K16/22C07K16/2863
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,723,074
App. No.
17/910,538
Granted
Sep 1, 2026
Kind
B2
Abstract

An object of the preset invention is to provide a medicament for treatment and/or prevention of cancer. The present invention relates to a medicament for treatment and/or prevention of cancer in a cancer patient with a previous history of another cancer treatment, comprising an antibody or a fragment thereof haying an immunological reactivity with CAPRIN-1 protein, and an angiogenesis inhibitor or an angiogenesis inhibitor and a taxane-based drug together or separately in combination.

Claims (66)

1 . A medicament for treatment of cancer, comprising (i) an antibody or a fragment thereof having an immunological reactivity with CAPRIN-1 protein, (ii) ramucirumab, and (iii) paclitaxel, nab-paclitaxel, or a combination of paclitaxel and nab-paclitaxel,

wherein the cancer is cancer expressing CAPRIN-1 protein on a cell membrane surface.

2 . The medicament according to claim 1 , wherein the antibody or the fragment thereof has an immunological reactivity with CAPRIN-1 protein having an amino acid sequence represented by any one of the even numbered SEQ ID NOs: 2 to 30.

3 . The medicament according to claim 1 , wherein the antibody or the fragment thereof has an immunological reactivity with an extracellular region of a CAPRIN-1 protein present on a cancer cell surface.

4 . The medicament according to claim 1 , wherein the antibody or the fragment thereof has an immunological reactivity with a partial polypeptide of CAPRIN-1 protein, the partial polypeptide having an amino acid sequence represented by any one of SEQ ID NOs: 31 to 35, 296 to 299, 308 and 309.

5 . The medicament according to claim 1 , wherein the antibody is a monoclonal antibody or a polyclonal antibody.

6 . The medicament according to claim 1 , wherein the antibody or a fragment thereof is any one of the following (A) to (M):

(A) an antibody or a fragment thereof comprising a heavy-chain variable region comprising complementarity determining regions of SEQ ID NOs: 36, 37 and 38 (CDR1, CDR2 and CDR3, respectively) and a light-chain variable region comprising complementarity determining regions of SEQ ID NOs: 40, 41 and 42 (CDR1, CDR2 and CDR3, respectively), and having an immunological reactivity with CAPRIN-1 protein;

(B) an antibody or a fragment thereof comprising a heavy-chain variable region comprising complementarity determining regions of SEQ ID NOs: 44, 45 and 46 (CDR1, CDR2 and CDR3, respectively) and a light-chain variable region comprising complementarity determining regions of SEQ ID NOs: 48, 49 and 50 (CDR1, CDR2 and CDR3, respectively), and having an immunological reactivity with CAPRIN-1 protein;

(C) an antibody or a fragment thereof comprising a heavy-chain variable region comprising complementarity determining regions of SEQ ID NOs: 52, 53 and 54 (CDR1, CDR2 and CDR3, respectively) and a light-chain variable region comprising complementarity determining regions of SEQ ID NOs: 56, 57 and 58 (CDR1, CDR2 and CDR3, respectively), and having an immunological reactivity with CAPRIN-1 protein;

(D) an antibody or a fragment thereof comprising a heavy-chain variable region comprising complementarity determining regions of SEQ ID NOs: 60, 61 and 62 (CDR1, CDR2 and CDR3, respectively) and a light-chain variable region comprising complementarity determining regions of SEQ ID NOs: 64, 65 and 66 (CDR1, CDR2 and CDR3, respectively), and having an immunological reactivity with CAPRIN-1 protein;

(E) an antibody or a fragment thereof comprising a heavy-chain variable region comprising complementarity determining regions of SEQ ID NOs: 170, 171 and 172 (CDR1, CDR2 and CDR3, respectively) and a light-chain variable region comprising complementarity determining regions of SEQ ID NOs: 173, 174 and 175 (CDR1, CDR2 and CDR3, respectively), and having an immunological reactivity with CAPRIN-1 protein;

(F) an antibody or a fragment thereof comprising a heavy-chain variable region comprising complementarity determining regions of SEQ ID NOs: 176, 177 and 178 (CDR1, CDR2 and CDR3, respectively) and a light-chain variable region comprising complementarity determining regions of SEQ ID NOs: 179, 180 and 181 (CDR1, CDR2 and CDR3, respectively), and having an immunological reactivity with CAPRIN-1 protein;

(G) an antibody or a fragment thereof comprising a heavy-chain variable region comprising complementarity determining regions of SEQ ID NOs: 182, 183 and 184 (CDR1, CDR2 and CDR3, respectively) and a light-chain variable region comprising complementarity determining regions of SEQ ID NOs: 185, 186 and 187 (CDR1, CDR2 and CDR3, respectively), and having an immunological reactivity with CAPRIN-1 protein;

(H) an antibody or a fragment thereof comprising a heavy-chain variable region comprising complementarity determining regions of SEQ ID NOs: 188, 189 and 190 (CDR1, CDR2 and CDR3, respectively) and a light-chain variable region comprising complementarity determining regions of SEQ ID NOs: 191, 192 and 193 (CDR1, CDR2 and CDR3, respectively), and having an immunological reactivity with CAPRIN-1 protein;

(I) an antibody or a fragment thereof comprising a heavy-chain variable region comprising complementarity determining regions of SEQ ID NOs: 146, 147 and 148 (CDR1, CDR2 and CDR3, respectively) and a light-chain variable region comprising complementarity determining regions of SEQ ID NOs: 149, 150 and 151 (CDR1, CDR2 and CDR3, respectively), and having an immunological reactivity with CAPRIN-1 protein;

(J) an antibody or a fragment thereof comprising a heavy-chain variable region comprising complementarity determining regions of SEQ ID NOs: 272, 273 and 274 (CDR1, CDR2 and CDR3, respectively) and a light-chain variable region comprising complementarity determining regions of SEQ ID NOs: 275, 276 and 277 (CDR1, CDR2 and CDR3, respectively), and having an immunological reactivity with CAPRIN-1 protein;

(K) an antibody or a fragment thereof comprising a heavy-chain variable region comprising complementarity determining regions of SEQ ID NOs: 290, 291 and 292 (CDR1, CDR2 and CDR3, respectively) and a light-chain variable region comprising complementarity determining regions of SEQ ID NOs: 293, 294 and 295 (CDR1, CDR2 and CDR3, respectively), and having an immunological reactivity with CAPRIN-1 protein;

(L) an antibody or a fragment thereof comprising a heavy-chain variable region comprising complementarity determining regions of SEQ ID NOs: 300, 301 and 302 (CDR1, CDR2 and CDR3, respectively) and a light-chain variable region comprising complementarity determining regions of SEQ ID NOs: 304, 305 and 306 (CDR1, CDR2 and CDR3, respectively), and having an immunological reactivity with CAPRIN-1 protein; and

(M) an antibody or a fragment thereof comprising a heavy-chain variable region comprising complementarity determining regions of SEQ ID NOs: 134, 135 and 136 (CDR1, CDR2 and CDR3, respectively) and a light-chain variable region comprising complementarity determining regions of SEQ ID NOs: 137, 138 and 139 (CDR1, CDR2 and CDR3, respectively), and having an immunological reactivity with CAPRIN-1 protein.

7 . The medicament according to claim 1 , wherein the antibody or the fragment thereof is any one of the following (a) to (al):

(a) an antibody or a fragment thereof comprising a heavy-chain variable region comprising the amino acid sequence of SEQ ID NO: 39 and a light-chain variable region comprising the amino acid sequence of SEQ ID NO: 43;

(b) an antibody or a fragment thereof comprising a heavy-chain variable region comprising the amino acid sequence of SEQ ID NO: 47 and a light-chain variable region comprising the amino acid sequence of SEQ ID NO: 51;

(c) an antibody or a fragment thereof comprising a heavy-chain variable region comprising the amino acid sequence of SEQ ID NO: 55 and a light-chain variable region comprising the amino acid sequence of SEQ ID NO: 59;

(d) an antibody or a fragment thereof comprising a heavy-chain variable region comprising the amino acid sequence of SEQ ID NO: 63 and a light-chain variable region comprising the amino acid sequence of SEQ ID NO: 67;

(e) an antibody or a fragment thereof comprising a heavy-chain variable region comprising the amino acid sequence of SEQ ID NO: 68 and a light-chain variable region comprising the amino acid sequence of SEQ ID NO: 69;

(f) an antibody or a fragment thereof comprising a heavy-chain variable region comprising the amino acid sequence of SEQ ID NO: 70 and a light-chain variable region comprising the amino acid sequence of SEQ ID NO: 71;

(g) an antibody or a fragment thereof comprising a heavy-chain variable region comprising the amino acid sequence of SEQ ID NO: 72 and a light-chain variable region comprising the amino acid sequence of SEQ ID NO: 73;

(h) an antibody or a fragment thereof comprising a heavy-chain variable region comprising the amino acid sequence of SEQ ID NO: 74 and a light-chain variable region comprising the amino acid sequence of SEQ ID NO: 75;

(i) an antibody or a fragment thereof comprising a heavy-chain variable region comprising the amino acid sequence of SEQ ID NO: 76 and a light-chain variable region comprising the amino acid sequence of SEQ ID NO: 77;

(j) an antibody or a fragment thereof comprising a heavy-chain variable region comprising the amino acid sequence of SEQ ID NO: 78 and a light-chain variable region comprising the amino acid sequence of SEQ ID NO: 79;

(k) an antibody or a fragment thereof comprising a heavy-chain variable region comprising the amino acid sequence of SEQ ID NO: 80 and a light-chain variable region comprising the amino acid sequence of SEQ ID NO: 81;

(l) an antibody or a fragment thereof comprising a heavy-chain variable region comprising the amino acid sequence of SEQ ID NO: 82 and a light-chain variable region comprising the amino acid sequence of SEQ ID NO: 83;

(m) an antibody or a fragment thereof comprising a heavy-chain variable region comprising the amino acid sequence of SEQ ID NO: 84 and a light-chain variable region comprising the amino acid sequence of SEQ ID NO: 85;

(n) an antibody or a fragment thereof comprising a heavy-chain variable region comprising the amino acid sequence of SEQ ID NO: 86 and a light-chain variable region comprising the amino acid sequence of SEQ ID NO: 87;

(o) an antibody or a fragment thereof comprising a heavy-chain variable region comprising the amino acid sequence of SEQ ID NO: 88 and a light-chain variable region comprising the amino acid sequence of SEQ ID NO: 89;

(p) an antibody or a fragment thereof comprising a heavy-chain variable region comprising the amino acid sequence of SEQ ID NO: 90 and a light-chain variable region comprising the amino acid sequence of SEQ ID NO: 91;

(q) an antibody or a fragment thereof comprising a heavy-chain variable region comprising the amino acid sequence of SEQ ID NO: 92 and a light-chain variable region comprising the amino acid sequence of SEQ ID NO: 93;

(r) an antibody or a fragment thereof comprising a heavy-chain variable region comprising the amino acid sequence of SEQ ID NO: 94 and a light-chain variable region comprising the amino acid sequence of SEQ ID NO: 95;

(s) an antibody or a fragment thereof comprising a heavy-chain variable region comprising the amino acid sequence of SEQ ID NO: 96 and a light-chain variable region comprising the amino acid sequence of SEQ ID NO: 97;

(t) an antibody or a fragment thereof comprising a heavy-chain variable region comprising the amino acid sequence of SEQ ID NO: 98 and a light-chain variable region comprising the amino acid sequence of SEQ ID NO: 99;

(u) an antibody or a fragment thereof comprising a heavy-chain variable region comprising the amino acid sequence of SEQ ID NO: 100 and a light-chain variable region comprising the amino acid sequence of SEQ ID NO: 101;

(v) an antibody or a fragment thereof comprising a heavy-chain variable region comprising the amino acid sequence of SEQ ID NO: 102 and a light-chain variable region comprising the amino acid sequence of SEQ ID NO: 103;

(w) an antibody or a fragment thereof comprising a heavy-chain variable region comprising the amino acid sequence of SEQ ID NO: 104 and a light-chain variable region comprising the amino acid sequence of SEQ ID NO: 105;

(x) an antibody or a fragment thereof comprising a heavy-chain variable region comprising the amino acid sequence of SEQ ID NO: 106 and a light-chain variable region comprising the amino acid sequence of SEQ ID NO: 107;

(y) an antibody or a fragment thereof comprising a heavy-chain variable region comprising the amino acid sequence of SEQ ID NO: 108 and a light-chain variable region comprising the amino acid sequence of SEQ ID NO: 109;

(z) an antibody or a fragment thereof comprising a heavy-chain variable region comprising the amino acid sequence of SEQ ID NO: 110 and a light-chain variable region comprising the amino acid sequence of SEQ ID NO: 111;

(aa) an antibody or a fragment thereof comprising a heavy-chain variable region comprising the amino acid sequence of SEQ ID NO: 112 and a light-chain variable region comprising the amino acid sequence of SEQ ID NO: 113;

(ab) an antibody or a fragment thereof comprising a heavy-chain variable region comprising the amino acid sequence of SEQ ID NO: 114 and a light-chain variable region comprising the amino acid sequence of SEQ ID NO: 115;

(ac) an antibody or a fragment thereof comprising a heavy-chain variable region comprising the amino acid sequence of SEQ ID NO: 116 and a light-chain variable region comprising the amino acid sequence of SEQ ID NO: 117;

(ad) an antibody or a fragment thereof comprising a heavy-chain variable region comprising the amino acid sequence of SEQ ID NO: 118 and a light-chain variable region comprising the amino acid sequence of SEQ ID NO: 119;

(ae) an antibody or a fragment thereof comprising a heavy-chain variable region comprising the amino acid sequence of SEQ ID NO: 120 and a light-chain variable region comprising the amino acid sequence of SEQ ID NO: 121;

(af) an antibody or a fragment thereof comprising a heavy-chain variable region comprising the amino acid sequence of SEQ ID NO: 122 and a light-chain variable region comprising the amino acid sequence of SEQ ID NO: 123;

(ag) an antibody or a fragment thereof comprising a heavy-chain variable region comprising the amino acid sequence of SEQ ID NO: 124 and a light-chain variable region comprising the amino acid sequence of SEQ ID NO: 125;

(ah) an antibody or a fragment thereof comprising a heavy-chain variable region comprising the amino acid sequence of SEQ ID NO: 126 and a light-chain variable region comprising the amino acid sequence of SEQ ID NO: 127;

(ai) an antibody or a fragment thereof comprising a heavy-chain variable region comprising the amino acid sequence of SEQ ID NO: 128 and a light-chain variable region comprising the amino acid sequence of SEQ ID NO: 129;

(aj) an antibody or a fragment thereof comprising a heavy-chain variable region comprising the amino acid sequence of SEQ ID NO: 130 and a light-chain variable region comprising the amino acid sequence of SEQ ID NO: 131;

(ak) an antibody or a fragment thereof comprising a heavy-chain variable region comprising the amino acid sequence of SEQ ID NO: 132 and a light-chain variable region comprising the amino acid sequence of SEQ ID NO: 133; and

(al) an antibody or a fragment thereof comprising a heavy-chain variable region comprising the amino acid sequence of SEQ ID NO: 303 and a light-chain variable region comprising the amino acid sequence of SEQ ID NO: 307.

8 . The medicament according to claim 1 , wherein the antibody is a human antibody, a humanized antibody, a chimeric antibody or a single chain antibody.

9 . An agent for increasing drug efficacy of a pharmaceutical composition for treatment of cancer comprising (i) an antibody or a fragment thereof having an immunological reactivity with CAPRIN-1 protein as an active ingredient, wherein the agent further comprises (ii) ramucirumab and (iii) paclitaxel, nab-paclitaxel, or a combination of paclitaxel and nab-paclitaxel, as active ingredients,

wherein the cancer is cancer expressing CAPRIN-1 protein on a cell membrane surface.

10 . A method for treating cancer, comprising administering (i) an antibody or a fragment thereof having an immunological reactivity with CAPRIN-1 protein, (ii) ramucirumab, and (iii) paclitaxel, nab-paclitaxel, or a combination of paclitaxel and nab-paclitaxel, to a subject in need thereof,

wherein the cancer is cancer expressing CAPRIN-1 protein on a cell membrane surface.

11 . The method according to claim 10 , wherein the cancer is cancer in a cancer patient who has not responded to cancer treatment with a medicament other than cancer treatment with a medicament comprising an antibody or a fragment thereof having an immunological reactivity with CAPRIN-1 protein, an angiogenesis inhibitor, and a taxane-based drug together or separately in combination.

12 . The method according to claim 10 , wherein the cancer is gastric cancer, breast cancer, kidney cancer, pancreatic cancer, colon cancer, bile duct cancer, melanoma, lung cancer, renal cell carcinoma, Hodgkin's lymphoma, head and neck cancer, mesothelioma, colorectal cancer, esophageal cancer, gastroesophageal junction cancer, hepatocellular carcinoma, glioblastoma, urothelial carcinoma, ovarian cancer, urinary bladder cancer, uterine cancer, primary central nervous system lymphoma, primary testicular lymphoma, biliary tract cancer, brain tumor, prostate cancer, leukemia, lymphoma, liver cancer, sarcoma, fibrosarcoma, mastocytoma, adrenocortical carcinoma, Ewing's tumor, multiple myeloma, testicular cancer, thyroid cancer, basal cell carcinoma, Paget's disease or skin cancer.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 12, 2022
From: OKANO, FUMIYOSHI; AKAZAWA, DAISUKE
To: TORAY INDUSTRIES, INC.
Reel/Frame 061066/0267 →
Priority Claims (1)
JP 2020-043021 · Mar 12, 2020 · national
Continuity (1)
Related Publication 20230129035A1 · Apr 27, 2023
References Cited (291)
US 5595756A · Bally et al. · 1997 [cited by applicant]
US 8709418B2 · Okano et al. · 2014 [cited by applicant]
US 8828398B2 · Kobayashi et al. · 2014 [cited by applicant]
US 8911740B2 · Saito et al. · 2014 [cited by applicant]
US 8937160B2 · Kobayashi et al. · 2015 [cited by applicant]
US 9115200B2 · Okano et al. · 2015 [cited by applicant]
US 9175074B2 · Okano et al. · 2015 [cited by applicant]
US 9180187B2 · Ido et al. · 2015 [cited by applicant]
US 9180188B2 · Kobayashi et al. · 2015 [cited by applicant]
US 9181334B2 · Kobayashi et al. · 2015 [cited by applicant]
US 9181348B2 · Kobayashi et al. · 2015 [cited by applicant]
US 9260513B2 · Kobayashi et al. · 2016 [cited by applicant]
US 9266958B2 · Kobayashi et al. · 2016 [cited by applicant]
US 9273128B2 · Okano et al. · 2016 [cited by applicant]
US 9273130B2 · Kobayashi et al. · 2016 [cited by applicant]
US 9412192B2 · Mandel et al. · 2016 [cited by applicant]
US 9416192B2 · Okano et al. · 2016 [cited by applicant]
US 9416193B2 · Saito et al. · 2016 [cited by applicant]
US 9428581B2 · Saito et al. · 2016 [cited by applicant]
US 9473993B2 · Sachs et al. · 2016 [cited by applicant]
US 9573993B2 · Okano et al. · 2017 [cited by applicant]
US 9862774B2 · Okano et al. · 2018 [cited by applicant]
US 9982059B2 · Okano et al. · 2018 [cited by applicant]
US 10946093B2 · Junttila · 2021 [cited by applicant]
US 12274745B2 · Okano et al. · 2025 [cited by applicant]
US 20050019845A1 · Harkins et al. · 2005 [cited by applicant]
US 20110256144A1 · Okano et al. · 2011 [cited by applicant]
US 20120294860A1 · Ido et al. · 2012 [cited by applicant]
US 20120301471A1 · Kobayashi et al. · 2012 [cited by applicant]
US 20120301476A1 · Okano · 2012 [cited by examiner]
US 20120321641A1 · Okano et al. · 2012 [cited by applicant]
US 20130045210A1 · Kobayashi et al. · 2013 [cited by applicant]
US 20130071398A1 · Saito et al. · 2013 [cited by applicant]
US 20140154261A1 · Okano et al. · 2014 [cited by applicant]
US 20140178373A1 · Kobayashi et al. · 2014 [cited by applicant]
US 20140186359A1 · Okano et al. · 2014 [cited by applicant]
US 20140193434A1 · Kobayashi et al. · 2014 [cited by applicant]
US 20140199311A1 · Kobayashi et al. · 2014 [cited by applicant]
US 20140271634A1 · Silwkowski et al. · 2014 [cited by applicant]
US 20150004171A1 · Kobayashi et al. · 2015 [cited by applicant]
US 20150044221A1 · Kobayashi et al. · 2015 [cited by applicant]
US 20150050283A1 · Okano et al. · 2015 [cited by applicant]
US 20150299314A1 · Saito et al. · 2015 [cited by applicant]
US 20160297889A1 · Okano · 2016 [cited by examiner]
US 20160354499A1 · Ghanbari et al. · 2016 [cited by applicant]
US 20170002090A1 · Wang et al. · 2017 [cited by applicant]
US 20170095571A1 · Ponte et al. · 2017 [cited by applicant]
US 20180000865A1 · Weissman et al. · 2018 [cited by applicant]
US 20180094322A1 · Dalerba et al. · 2018 [cited by applicant]
US 20180169230A1 · Adams et al. · 2018 [cited by applicant]
US 20180312603A1 · Okano et al. · 2018 [cited by applicant]
US 20180362443A1 · Lavallee et al. · 2018 [cited by applicant]
US 20200054762A1 · Okano et al. · 2020 [cited by applicant]
US 20210121562A1 · Okano et al. · 2021 [cited by applicant]
US 20220072167A1 · Ludwig et al. · 2022 [cited by applicant]
US 20230129035A1 · Okano et al. · 2023 [cited by applicant]
US 20230139178A1 · Okano · 2023 [cited by applicant]
US 20230140155A1 · Okano · 2023 [cited by applicant]
US 20230159635A1 · Okano · 2023 [cited by applicant]
US 20230165957A1 · Okano et al. · 2023 [cited by applicant]
US 20250228937A1 · Okano et al. · 2025 [cited by applicant]
EP 2322221A1 · 2011 [cited by applicant]
EP 2324842A1 · 2011 [cited by applicant]
EP 2532367A1 · 2012 [cited by applicant]
EP 2301528B1 · 2013 [cited by applicant]
EP 2818481A1 · 2014 [cited by applicant]
EP 2818482A1 · 2014 [cited by applicant]
EP 2832365A1 · 2015 [cited by applicant]
EP 2832366A1 · 2015 [cited by applicant]
EP 2818481B1 · 2019 [cited by applicant]
EP 3777888A1 · 2021 [cited by applicant]
EP 4119156A1 · 2023 [cited by applicant]
EP 4119158A1 · 2023 [cited by applicant]
JP 2005512961A · 2005 [cited by applicant]
JP 2007527403A · 2007 [cited by applicant]
JP 2015502958A · 2015 [cited by applicant]
JP 2015127308A · 2015 [cited by applicant]
JP 2017510548A · 2017 [cited by applicant]
JP 2017535548A · 2017 [cited by applicant]
JP 2018502892A · 2018 [cited by applicant]
JP 2018516263A · 2018 [cited by applicant]
JP 2018518476A · 2018 [cited by applicant]
JP 2018527383A · 2018 [cited by applicant]
JP 2019504029A · 2019 [cited by applicant]
JP 2019527698A · 2019 [cited by applicant]
JP 2022516170A · 2022 [cited by applicant]
KR 1020140130670A · 2014 [cited by applicant]
WO WO03024442A2 · 2003 [cited by applicant]
WO WO2009142810A2 · 2009 [cited by applicant]
WO WO2010016526A1 · 2010 [cited by applicant]
WO WO2010080345A1 · 2010 [cited by applicant]
WO WO2011096517A1 · 2011 [cited by applicant]
WO WO2011096519A1 · 2011 [cited by applicant]
WO WO2011096528A1 · 2011 [cited by applicant]
WO WO2011096533A1 · 2011 [cited by applicant]
WO WO2011096534A1 · 2011 [cited by applicant]
WO WO2011096535A1 · 2011 [cited by applicant]
WO WO2013018883A1 · 2013 [cited by applicant]
WO WO2013018889A1 · 2013 [cited by applicant]
WO WO2013018891A1 · 2013 [cited by applicant]
WO WO2013018892A1 · 2013 [cited by applicant]
WO WO2013018894A1 · 2013 [cited by applicant]
WO WO2013086260A2 · 2013 [cited by applicant]
WO WO2013125630A1 · 2013 [cited by applicant]
WO WO2013125636A1 · 2013 [cited by applicant]
WO WO2013125654A1 · 2013 [cited by applicant]
WO WO2013147176A1 · 2013 [cited by applicant]
WO WO2014195852A1 · 2014 [cited by applicant]
WO WO2015020212A1 · 2015 [cited by applicant]
WO WO2015112749A2 · 2015 [cited by applicant]
WO WO2016004875A1 · 2016 [cited by applicant]
WO WO2016077227A2 · 2016 [cited by applicant]
WO WO2016193955A1 · 2016 [cited by applicant]
WO WO2017031367A1 · 2017 [cited by applicant]
WO WO2017112838A1 · 2017 [cited by applicant]
WO WO2018023197A1 · 2018 [cited by applicant]
WO WO2018079740A1 · 2018 [cited by applicant]
WO WO2018213302A1 · 2018 [cited by applicant]
WO WO2018234879A1 · 2018 [cited by applicant]
WO WO2019155448A1 · 2019 [cited by applicant]
WO WO2019189780A1 · 2019 [cited by applicant]
WO WO2020000704A1 · 2020 [cited by applicant]
WO WO2021154761A1 · 2021 [cited by applicant]
WO WO2021182570A1 · 2021 [cited by applicant]
WO WO2021182571A1 · 2021 [cited by applicant]
WO WO2021182572A1 · 2021 [cited by applicant]
WO WO2021182573A1 · 2021 [cited by applicant]
WO WO2021182574A1 · 2021 [cited by applicant]
WO WO2022270523A1 · 2022 [cited by applicant]
WO WO2022270524A1 · 2022 [cited by applicant]
WO WO2023008459A1 · 2023 [cited by applicant]
WO WO2023008461A1 · 2023 [cited by applicant]
WO WO2023008462A1 · 2023 [cited by applicant]
WO WO2023033129A1 · 2023 [cited by applicant]
WO WO2025058000A1 · 2025 [cited by applicant]
Chan et al., Annals of Oncology. vol. 21: 2305-2315. (Year: 2010). [cited by examiner]
“A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors,” ClinicalTrials.gov, NCT03872947, Mar. 13, 2019, pp. 1-10. [cited by applicant]
“A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors,” ClinicalTrials.gov, NCT03872947, Unique Protocol ID 950P1V02, Aug. 28, 2019, 12 pages total. [cited by applicant]
Extended European Search Report for European Application No. 21767020.7, dated Apr. 8, 2024. [cited by applicant]
Extended European Search Report for European Application No. 21768178.2, dated Apr. 9, 2024. [cited by applicant]
Extended European Search Report for European Application No. 21768433.1, dated Feb. 28, 2024. [cited by applicant]
Hanna et al., “A Ph-Ib study of TRK-950 combined with anti-cancer treatment regimens in patients with advanced solid tumors,” European Journal of Cancer, 34th EORTC-NCI-AACR Symposium, vol. 174S1, Oct. 26, 2022, pp. S32… [cited by applicant]
“A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors”, ClinicalTrials.gov, [online], Mar. 13, 2019, total 12 pages. [cited by applicant]
“A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors”, ClinicalTrials.gov, Mar. 13, 2019, total 12 pages. https://Clinicaltrials.gov/ct2/show/NCT03872947?term=TR… [cited by applicant]
International Search Report, issued in PCT/JP2021/009798, PCT/ISA/210, dated Apr. 20, 2021. [cited by applicant]
Kadowaki et al., “Multicenter phase I/II study of nivolumab combined with paclitaxel plus ramucirumab as the second-line treatment in patients with advanced gastric cancer”, the ESMO World Congress on Gastrointestinal C… [cited by applicant]
Wilke et al., “Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 … [cited by applicant]
Written Opinion of the International Searching Authority, issued in PCT/JP2021/009798, PCT/ISA/237, dated Apr. 20, 2021. [cited by applicant]
International Search Report for International Application No. PCT/JP2023/024125, dated Sep. 12, 2023. [cited by applicant]
Australian Office Action for Australian Application No. 2019242520, dated Feb. 17, 2025. [cited by applicant]
“Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma,” ClinicalTrials.gov, Sep. 8, 2017, 9 pages total. [cited by applicant]
Aghajanian et al., “OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal… [cited by applicant]
Alt et al., “Enfortumab Vedotin in urothelial cancer,” Therapeutic Advances in Urology, vol. 12, 2020; pp. 1-10. [cited by applicant]
Anonymous, “History of Changes for Study: NCT03276832, Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma”, ClinicalTrials.gov, Dec. 20, 2017, pp. 1-5. [cited by applicant]
Auerbach et al., “Angiogenesis assays: Problems and pitfalls,” Cancer and Metastasis Reviews, vol. 19, 2000, pp. 167-172. [cited by applicant]
Barth et al., “Prognostic Factors in 1,521 Melanoma Patients With Distant Metastases,” Journal of the American College of Surgeons, vol. 181, No. 3, 1995, pp. 193-201. [cited by applicant]
Berman et al., “Novel Dermatologic Uses of the Immune Response Modifier Imiquimod 5% Cream”, Skin Therapy Letter, vol. 7, No. 9, 2002, pp. 1-6. [cited by applicant]
Brown et al., “Tolerance to Single, but Not Multiple, Amino Acid Replacements in Antibody VH CDR2—A Means of Minimizing B Cell Wastage from Somatic Hypermutation?,” Journal of Immunology, vol. 156, 1996, pp. 3285-3291. [cited by applicant]
Campione et al., “Lack of efficacy of imiquimod in patients with basal cell carcinoma previously treated with rituximab for B cell lymphoma: two case reports,” Journal of Medical Case Reports, vol. 10, No. 57, 2016, pp.… [cited by applicant]
Christiansen et al., “Biological impediments to monoclonal antibody-based cancer immunotherapy,” Molecular Cancer Therapeutics, vol. 3, No. 11, 2004, pp. 1493-1501. [cited by applicant]
Ciardiello et al., “Antitumor Activity of Sequential Treatment with Topotecan and Anti-Epidermal Growth Factor Receptor Monoclonal Antibody C225,” Clinical Cancer Research, vol. 5, No. 4, 1999, pp. 909-916. [cited by applicant]
Cohen et al., “Treatment of Extramammary Paget Disease with Topical Imiquimod Cream: Case Report and Literature Review,” Southern Medical Journal, vol. 99, pp. 396-402. 2006. [cited by applicant]
Colombo et al., “Treatment of recurrent ovarian cancer relapsing 6-12 months post platinum-based chemotherapy,” Critical Reviews in Oncology/Hematology, vol. 64, 2007, pp. 129-138. [cited by applicant]
Corraliza-Gorjón et al., “New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness,” Frontiers in Immunology, vol. 8, 2017, pp. 1-31. [cited by applicant]
Douillard et al., “Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial,” The Lancet, vol. 355, 2000, pp. 1041-1… [cited by applicant]
Dummer et al., “Imiquimod in basal cell carcinoma: how does it work?,” British Journal of Dermatology, vol. 149; Suppl. 66, 2003, pp. 57-58. [cited by applicant]
Extended European Search Report for European Application No. 19774904.7, dated Oct. 29, 2021. [cited by applicant]
Ferrandina et al., “Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Progressive or Recurrent Ovarian Cancer,” Journal of Clinical Oncology, vol. 26, No. 6, 2008, pp. 890-896. [cited by applicant]
Gordon et al., “Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan,” Journal of Clinical Oncology, vol. 19, No. 14, 2001, pp. 3312-3322. [cited by applicant]
Greenshields et al., “Imiquimod induces reactive oxygen species- and caspase-independent cell cycle arrest and apoptosis in MDA-MB-468 breast cancer cells,” Molecular Cancer Therapeutics, vol. 8, Issue 12, supplement, a… [cited by applicant]
Gura, “Systems for Identifying New Drugs Are Often Faulty,” Science, vol. 278, 1997, pp. 1041-1042. [cited by applicant]
Hammond et al., “Pharmacologic resistance in colorectal cancer: a review,” Therapeutic Advances in Medical Oncology, vol. 8, No. 1, 2016, pp. 57-84. [cited by applicant]
Henriques et al., “Imiquimod in the Treatment of Breast Cancer Skin Metastasis,” Journal of Clinical Oncology, vol. 32, No. 8, 2014, pp. e22-e25. [cited by applicant]
Hogenesch et al., “Challenges in pre-clinical testing of anti-cancer drugs in cell culture and in animal models,” Journal of Controlled Release, vol. 164, No. 2, 2012, pp. 183-186. [cited by applicant]
Hou et al., “Tunicamycin Potentiates Cisplatin Anticancer Efficacy through the DPAGT1/Akt/ABCG2 Pathway in Mouse Xenograft Models of Human Hepatocellular Carcinoma,” Molecular Cancer Therapeutics, vol. 12, No. 12, 2013,… [cited by applicant]
Imai, “HDAC inhibitors for treatment of multiple myeloma,” Hematology, vol. 78, No. 1, 2019, pp. 18-24, with a partial English translation. [cited by applicant]
International Search Report for International Application No. PCT/JP2019/014044, dated May 21, 2019. [cited by applicant]
International Search Report for International Application No. PCT/JP2021/009795, dated Apr. 20, 2021. [cited by applicant]
International Search Report for International Application No. PCT/JP2021/009796, dated Apr. 20, 2021. [cited by applicant]
International Search Report for International Application No. PCT/JP2021/009797, dated Apr. 20, 2021. [cited by applicant]
International Search Report for International Application No. PCT/JP2021/009799, dated Apr. 20, 2021. [cited by applicant]
International Search Report for International Application No. PCT/JP2022/024812, dated Sep. 13, 2022. [cited by applicant]
International Search Report for International Application No. PCT/JP2022/024814, dated Sep. 13, 2022. [cited by applicant]
International Search Report for International Application No. PCT/JP2022/028871, dated Sep. 27, 2022. [cited by applicant]
International Search Report for International Application No. PCT/JP2022/028877, dated Oct. 18, 2022. [cited by applicant]
International Search Report for International Application No. PCT/JP2022/028878, dated Oct. 18, 2022. [cited by applicant]
Ishida et al., “Regimen Selection for First-line FOLFIRI and FOLFOX Based on UGT1A1 Genotype and Physical Background is Feasible in Japanese Patients with Advanced Colorectal Cancer,” Japanese Journal of Clinical Oncolo… [cited by applicant]
Ishii, “MEK/RAF, Big-name cancer molecular targets that have finally came—R&D of MAPK pathway inhibitors,” Folia Pharmacologica Japonica, vol. 141, 2013, pp. 15-21, with an English translation. [cited by applicant]
Jain et al., “Current ADC Linker Chemistry,” Pharmaceutical Research, vol. 32, 2015, pp. 3526-3540. [cited by applicant]
Jain, “Barriers to Drug Delivery in Solid Tumors,” Scientific American, 1994, pp. 58-65. [cited by applicant]
Joseph et al., “Treatment of in-transit and metastatic melanoma in two patients treated with ipilimumab and topical imiquimod,” Melanoma Research, vol. 26, No. 4, 2016, pp. 409-412. [cited by applicant]
Kitchen et al., “Comment on The efficacy and toxicity of gemcitabine, carboplatin and bevacizumab in metastatic breast cancer,” British Journal of Cancer, vol. 109, 2013, pp. 526-528. [cited by applicant]
Komiyama et al., “Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of ovarian cancer including primary peritoneal cancer and fallopian tube cancer,” International Journal of Clinical Oncology, vol… [cited by applicant]
Kussie et al., “A Single Engineered Amino Acid Substitution Changes Antibody Fine Specificity,” Journal of Immunology, 1994, pp. 146-152. [cited by applicant]
Larkin et al., “Five-Year Survival with Combined Nivolumab and Ipilimumuab in Advanced Melanoma,” New England Journal of Medicine, vol. 381, 2019, pp. 1535-1546. [cited by applicant]
Lee et al., “Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity,” International Journal of Molecular Sciences, vol. 21, 2020, pp. 1-29. [cited by applicant]
Li et al., “Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity,” Nature Communications, vol. 7, 2016, pp. 1-11. [cited by applicant]
Li et al., “HDACs and HDAC Inhibitors in Cancer Development and Therapy,” Cold Spring Harbor Perspectives in Medicine, vol. 6, 2016, pp. 1-34. [cited by applicant]
Lito et al., “Tumor adaptation and resistance to RAF inhibitors,” Nature Medicine, vol. 19, No. 11, 2013, pp. 1401-1409. [cited by applicant]
Liu et al., “BRAF/MEK inhibitors promote CD47 expression that is reversible by ERK inhibition in melanoma,” Oncotarget, vol. 8, No. 41, 2017, pp. 69477-69492. [cited by applicant]
Mereiter et al., “Glycosylation in the Era of Cancer-Targeted Therapy: Where Are We Heading?,” Cancer Cell, vol. 36, 2019, pp. 6-16. [cited by applicant]
Metzger-Filho et al., “Dissecting the Heterogeneity of Triple-Negative Breast Cancer,” Journal of Clinical Oncology, vol. 30, 2012, pp. 1879-1887. [cited by applicant]
Mitachi et al., “DPAGT1 Inhibitors of Capuramycin Analogues and Their Antimigratory Activities of Solid Tumors,” Journal of Medicinal Chemistry, vol. 63, 2020, pp. 10855-10878. [cited by applicant]
Omura et al., “Phase III Trial of Paclitaxel at Two Dose Levels, the Higher Dose Accompanied by Filgrastim at Two Dose Levels in Platinum-Pretreated Epithelial Ovarian Cancer: An Intergroup Study,” Journal of Clinical O… [cited by applicant]
Park et al., “A short guide to histone deacetylases including recent progress on class II enzymes,” Experimental & Molecular Medicine, vol. 52, 2020, pp. 204-212. [cited by applicant]
Peyssonnaux et al., “The Raf/MEK/ERK pathway: new concepts of activation,” Biology of the Cell, vol. 93, 2001, pp. 53-62. [cited by applicant]
Peyton et al., “Downstaging and Survival Outcomes Associated With Neoadjuvant Chemotherapy Regimens Among Patients Treated With Cystectomy for Muscle-Invasive Bladder Cancer,” JAMA Oncology, vol. 4, No. 11, 2018, pp. 15… [cited by applicant]
Pfisterer et al., “Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial,” Lancet Oncology, vol. 21, 2020, pp. 699-709. [cited by applicant]
Pujade-Lauraine et al., “Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial,” Journal of Clinical Oncology, vol. 32, No. 13, 2014, p… [cited by applicant]
Rose et al., “Prolonged Oral Etoposide as Second-Line Therapy for Platinum-Resistant and Platinum-Sensitive Ovarian Carcinoma: A Gynecologic Oncology Group Study,” Journal of Clinical Oncology, vol. 16, No. 2, 1998, pp.… [cited by applicant]
Rowinsky et al., “Review of Phase I Clinical Studies With Topotecan,” Seminars in Oncology, vol. 24, No. 6, 1997, pp. S20-3-S20-10. [cited by applicant]
Salazar et al., “Topical Imiquimod Plus Nab-paclitaxel for Breast Cancer Cutaneous Metastases—A Phase 2 Clinical Trial,” JAMA Oncology, vol. 3, No. 7, 2017, pp. 969-973. [cited by applicant]
Shroff et al., “Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers—A Phase 2 Clinical Trial,” JAMA Oncology, vol. 5, No. 6, 2019, pp. 824-830. [cited by applicant]
Siegel et al., “Colorectal Cancer Statistics, 2014,” CA: A Cancer Journal for Clinicians, vol. 64, 2014, pp. 104-117. [cited by applicant]
Sporn et al., “Chemoprevention of cancer,” Carcinogenesis, vol. 21, No. 3, 2000, pp. 525-530. [cited by applicant]
Study NCT03276832. National Cancer Institute (NCI): Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma—ClinicalTrials.gov, Dec. 20, 2017 (v2), URL: https:/clinicaltrials.gov/ct2/history/NCT0327… [cited by applicant]
Sun et al., “Targeting glycosylated PD-1 induces potent anti-tumor immunity,” Cancer Research, vol. 80, No. 11, 2020, pp. 2298-2310. [cited by applicant]
Suraweera et al., “Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi,” Frontiers in Oncology, vol. 8, 2018, pp. 1-15. [cited by applicant]
Thomas et al., “Antibody-drug conjugates for cancer therapy,” Lancet Oncology, vol. 17, No. 6, 2016, pp. e254-e262. [cited by applicant]
Topp et al., “Antibody transport in cultured tumor cell layers,” Journal of Controlled Release, vol. 53, 1998, pp. 15-23. [cited by applicant]
Vajdos et al., “Comprehensive Functional Maps of the Antigen-binding Site of an Anti-ErbB2 Antibody Obtained with Shotgun Scanning Mutagenesis,” Journal of Molecular Biology, vol. 320, 2002, pp. 415-428. [cited by applicant]
Wojtowicz et al., “Inhibition of protein glycosylation reverses the MDR phenotype of cancer cell lines,” Biomedicine & Pharmacotherapy, vol. 74, 2015, pp. 49-56. [cited by applicant]
Wu et al., “Tunicamycin specifically aggravates ER stress and overcomes chemoresistance in multidrug-resistant gastric cancer cells by inhibiting N-glycosylation,” Journal of Experimental & Clinical Cancer Research, vol… [cited by applicant]
Yuan et al., “The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy,” Journal of Hematology & Oncology, vol. 13, No. 113, 2020, pp. 1-19. [cited by applicant]
Zechmeister, “Progress in the Chemistry of Organic Natural Products,” Springer Chemistry, 1997, 86 pages total. [cited by applicant]
Amodio et al., “EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer,” Cancer Discovery, vol. 10, Aug. 2020, pp. 1129-1139. [cited by applicant]
Du et al., “Inhibition of ERAD synergizes with FTS to eradicate pancreatic cancer cells,” BMC Cancer, vol. 21, No. 237, 2021, pp. 1-13. [cited by applicant]
Extended European Search Report for European Application No. 22849523.0, dated Oct. 15, 2025. [cited by applicant]
Golas et al., “SKI-606, a Src/Abl Inhibitor with In vivo Activity in Colon Tumor Xenograft Models,” Cancer Research, vol. 65, No. 12, Jun. 15, 2005, pp. 5358-5364. [cited by applicant]
Hochster et al., “Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer,” Cancer Chemother Pharmacol, vol. 75, 2015, pp. 17-23. [cited by applicant]
Jain et al., “Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia,” Am J Hematol., vol. 96, 2… [cited by applicant]
Kim et al., “Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients,” Cell, vol. 183, Nov. 12, 2020, pp. 850-859. [cited by applicant]
Kunnimalaiyaan et al., “Neuroendocrine tumor cell growth inhibition by ZM336372 through alterations in multiple signaling pathways,” Surgery, vol. 142, No. 6, Dec. 2007, pp. 959-964. [cited by applicant]
Liang et al., “SCH 66336 (Lonafarnib), a farnesyl transferase inhibitor, demonstrates enhanced antitumor efficacy in combination with the alkylating agent Temozolomide, Cisplatin, and Carboplatin,” Proceedings of the Am… [cited by applicant]
Pal R et al., “Stem-like colorectal cancer cell lines show response to the ERK1/2 inhibitor, SCH772984, alone and in combination with neratinib,” EMBASE, Accession No. EMB-619155942, Jul. 1, 2017, 4 pages total. [cited by applicant]
Sanz-Garcia et al., “BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives,” Annals of Oncology, vol. 28, Issue 11, 2017, pp. 2648-2657. [cited by applicant]
U.S. Office Action for U.S. Appl. No. 17/910,549, dated Nov. 13, 2025. [cited by applicant]
Wong et al., “Lonafarnib for cancer and progeria,” Expert Opinion on Investigational Drugs, vol. 21, No. 7, 2012, pp. 1043-1055. [cited by applicant]
“A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors,” National Library of Medicine, ClinicalTrials.gov, NCT03872947, Version 1, Mar. 13, 2019, pp. 1-18. [cited by applicant]
Azmy et al., “Gemcitabine Plus Carboplatin in Patients with Advanced Hepatocellular Carcinoma: Results of a Phase II Study,” ISRN Oncology, vol. 2012, Article ID 420931, 2012, pp. 1-5. [cited by applicant]
Eisenhauer et al., “A phase II study of gemcitabine, carboplatin and bevacizumab for the treatment of platinum-sensitive recurrent ovarian cancer,” Gynecologic Oncology, vol. 134, 2014, pp. 262-266. [cited by applicant]
Pignata et al., “Treatment of recurrent ovarian cancer,” Annals of Oncology, vol. 28 (Supplement 8), Nov. 2017, pp. viii51-viii56. [cited by applicant]
Suresh et al., “Gemcitabine and carboplatin in the treatment of metastatic cholangiocarcinoma and gallbladder cancer,” Journal of Clinical Oncology, vol. 25, No. 18 Suppl, 2007, pp. 1-2, abstract provided only. [cited by applicant]
U.S. Office Action for U.S. Appl. No. 17/910,544, dated Sep. 17, 2025. [cited by applicant]
Lloyd et al., “Modelling the Human Immune Response: Performance of a 10 [cited by applicant]
U.S. Office Action for U.S. Appl. No. 17/910,532, dated Aug. 25, 2025. [cited by applicant]
Wikipedia, “List of Cancer Types,” 2020, pp. 1-7. [cited by applicant]
“What is Cancer?”, National Cancer Institute, 2020, pp. 1-8. [cited by applicant]
Extended European Search Report for European Application No. 22828440.2, dated May 27, 2025. [cited by applicant]
Okano et al., “Identification of Membrane-expressed CAPRIN-1 as a Novel and Universal Cancer Target, and Generation of a Therapeutic Anti-CAPRIN-1 Antibody TRK-950,” Cancer Research Communications, vol. 3, No. 4, XP0932… [cited by applicant]
U.S. Office Action for U.S. Appl. No. 17/910,544, dated Jun. 17, 2025. [cited by applicant]
Vanderbeeken et al., “Topoisomerase Inhibitors in Metastatic Breast Cancer: Overview of Current Practice and Future Development,” Current Breast Cancer Reports, vol. 5, XP035340237, 2013, pp. 31-41. [cited by applicant]
Banerjee et al., “Benefits and Pitfalls of a Glycosylation Inhibitor Tunicamycin in the Therapeutic Implication of Cancers,” Cells, vol. 13, No. 5, XP093285590, Feb. 25, 2024, pp. 1-16. [cited by applicant]
Esko et al., “Chapter 40—Natural and Synthetic Inhibitors of Glycosylation,” Essentials of Glycobiology, XP093285359, Jan. 1, 1999, pp. 1-18. [cited by applicant]
Extended European Search Report for European Application No. 22849522.2, dated Jul. 14, 2025. [cited by applicant]
Han et al., “Tunicamycin enhances the antitumor activity of trastuzumab on breast cancer in vitro and in vivo,” Oncotarget, vol. 6, No. 36, XP093285591, Oct. 12, 2015, pp. 38912-38925. [cited by applicant]
“A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors,” National Library of Medicine, NCT03872947, Aug. 3, 2025, 24 pages total. [cited by applicant]
Australian Office Action for Australian Application No. 2019242520, dated Jan. 16, 2026. [cited by applicant]
Korean Office Action for Korean Application No. 10-2022-7035177, dated Jan. 9, 2026. [cited by applicant]
Lipman et al., “Monoclonal Versus Polyclonal Antibodies: Distinguishing Characteristics, Applications, and Information Resources,” ILAR Journal, vol. 46, No. 3, 2005, pp. 258-268. [cited by applicant]
Pfisterer et al., “Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG,” Journal of C… [cited by applicant]
Ha et al., “Mycophenolic acid inhibits mesangial cell activation through p38 MAPK inhibition,” Life Sciences, vol. 79, 2006, pp. 1561-1567. [cited by applicant]
Hatzivassiliou et al., “Mechanism of MEK inhibition determines efficacy in mutant KRAS-versus BRAF-driven cancers,” Nature, vol. 501, 2013, pp. 1-5 (6 pages total). [cited by applicant]
Li et al., “MEK Inhibitor Augments Antitumor Activity of B7-H3-Redirected Bispecific Antibody,” Frontiers in Oncology, vol. 10, Article 1527, Aug. 25, 2020, pp. 1-15. [cited by applicant]
Moreno et al., “Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma,” OncoImmunology, vol. 5, Issue 7, Jul. 2016, pp. e1052212-1-e1052212-8. [cited by applicant]
Partial Supplementary European Search Report for European Application No. 22828439.4, dated Jun. 20, 2025. [cited by applicant]
Partial Supplementary European Search Report for European Application No. 22849523.0, dated Jun. 20, 2025. [cited by applicant]
Toray Industries, “A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors,” ClinicalTrials.gov, NCT03872947, Mar. 27, 2020, pp. 1-19. [cited by applicant]
Xie et al., “Systemic treatment options for advanced biliary tract carcinoma,” The Japanese Society of Gastroenterology, vol. 55, 2020, pp. 944-957. [cited by applicant]
Abdelaziz et al., “A purified and lyophilized Pseudomonas aeruginosa derived pyocyanin induces promising apoptotic and necrotic activities against MCF-7 human breast adenocarcinoma,” Microbial Cell Factories, vol. 21, A… [cited by applicant]
Aikawa et al., “Cell death induced by dorsomorphin in adult T-cell leukemia/lymphoma is AMPK-independent,” The FEBS Journal, vol. 287, No. 18, 2020, pp. 4005-4015. [cited by applicant]
Duffy et al., “GSK3 Inhibitors Regulate MYCN mRNA Levels and Reduce Neuroblastoma Cell Viability through Multiple Mechanisms, Including p53 and Wnt Signaling,” Molecular Cancer Therapeutics, vol. 13, No. 2, Feb. 2014, p… [cited by applicant]
English translation of the International Search Report for International Application No. PCT/JP2024/012990, dated Jun. 18, 2024. [cited by applicant]
Gong et al., “Caprin-1 is a novel microRNA-223 target for regulation the proliferation and invasion of human breast cancer cells,” Biomedicine & Pharmacotherapy, vol. 67, No. 7, 2013, pp. 629-636. [cited by applicant]
He et al., “Baicalein and Ly294002 induces liver cancer cells apoptosis via regulating phosphatidyl inositol 3-kinase/Akt signaling pathway,” Journal of Cancer Research and Therapeutics, vol. 14, Supplement Issue 2, 201… [cited by applicant]
Katoh, “Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review),” International Journal of Oncology, v… [cited by applicant]
Liu et al., “The AMPK Inhibitor Compound C Is a Potent AMPK-Independent Antiglioma Agent,” Molecular Cancer Therapeutics, vol. 13, No. 3, Mar. 2014, pp. 596-605. [cited by applicant]
Shin, “Laboratory of Molecular and Cellular Biology, Graduate School of Biostudies,” Overview of Graduate School and Faculty of Pharmaceutical Sciences, Kyoto University, Sep. 2018, p. 43 (4 pages total), with partial E… [cited by applicant]
Wang et al., “Dynasore-induced potent ubiquitylation of the exon 19 deletion mutant of epidermal growth factor receptor suppresses cell growth and migration in non-small cell lung cancer,” International Journal of Bioch… [cited by applicant]
Wehbe et al., “Pifithrin-α Enhances Chemosensitivity by a p38 Mitogen-Activated Protein Kinase-Dependent Modulation of the Eukaryotic Initiation Factor 4E in Malignant Cholangiocytes,” The Journal of Pharmacology and Ex… [cited by applicant]
Yin et al., “Glycogen Synthase Kinase 3β Inhibition as a Therapeutic Approach in the Treatment of Endometrial Cancer,” International Journal of Molecular Sciences, vol. 14, No. 8, Aug. 12, 2013, pp. 16617-16637. [cited by applicant]
Yue et al., “Gain-of-function mutant p53 activates small GTPase Rac1 through SUMOylation to promote tumor progression,” Genes & Development, vol. 31, No. 16, 2017, pp. 1641-1654 (15 pages total). [cited by applicant]
“Cancer Risk and Prevention,” American Cancer Society, https://www.cancer.org/cancer/risk-prevention.html, Nov. 13, 2025, pp. 1-7. [cited by applicant]
Edwards et al., “The Remarkable Flexibility of the Human Antibody Repertoire; Isolation of Over One Thousand Different Antibodies to a Single Protein, BLyS,” Journal of Molecular Biology, vol. 334, 2003, pp. 103-118. [cited by applicant]
Muro et al., “Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS s… [cited by applicant]
Schultheis et al., “Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study,” Annals of Oncology, vol. 24, 2013, pp. 1560-1567. [cited by applicant]
Sela-Culang et al., “The structural basis of antibody-antigen recognition,” Frontiers in Immunology, vol. 4, Article 302, Oct. 2013, pp. 1-13. [cited by applicant]
U.S. Office Action for U.S. Appl. No. 17/910,522, dated Nov. 28, 2025. [cited by applicant]
English translation of the International Search Report for International Application No. PCT/JP2024/032627, dated Dec. 3, 2024. [cited by applicant]
Lewington et al., “Bone-Seeking Radionuclides for Therapy,” The Journal of Nuclear Medicine, vol. 46, No. 1 (Suppl), Jan. 2005, pp. 38S-47S. [cited by applicant]
Reubi et al., “Candidates for Peptide Receptor Radiotherapy Today and in the Future,” The Journal of Nuclear Medicine, vol. 46, No. 1 (Suppl), Jan. 2005, pp. 67S-75S. [cited by applicant]